|Year : 2021 | Volume
| Issue : 2 | Page : 191-193
ISPD DIGICON 2020: Celebrating 25 glorious years' of brilliant service in the field of pediatric dermatology, leaving lasting footprints amid the COVID pandemic
Sanober B Daruwalla
Consultant Dermatologist, Godrej Baug, Off NepeanSea Road, Mumbai, Maharashtra, India
|Date of Submission||10-Nov-2021|
|Date of Decision||13-Nov-2021|
|Date of Acceptance||17-Nov-2021|
|Date of Web Publication||31-Mar-2021|
Sanober B Daruwalla
Consultant Dermatologist, Godrej Baug, Off NepeanSea Road, Mumbai, Maharashtra
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Daruwalla SB. ISPD DIGICON 2020: Celebrating 25 glorious years' of brilliant service in the field of pediatric dermatology, leaving lasting footprints amid the COVID pandemic. Indian J Paediatr Dermatol 2021;22:191-3
|How to cite this URL:|
Daruwalla SB. ISPD DIGICON 2020: Celebrating 25 glorious years' of brilliant service in the field of pediatric dermatology, leaving lasting footprints amid the COVID pandemic. Indian J Paediatr Dermatol [serial online] 2021 [cited 2021 Apr 18];22:191-3. Available from: https://www.ijpd.in/text.asp?2021/22/2/191/312812
The Indian Society for Pediatric Dermatology (ISPD), the only organization in the country dedicated to educating and catering to all aspects pertinent to “pediatric dermatology,” was all set to celebrate its completion of 25 beautiful years this year. However, the onslaught of the COVID pandemic did not only halt all celebrations but also brought personal communication to a standstill and reignited the basic survival instinct among the human race. However, among the pandemonium, the team of ISPD known to deliver their insights year after year to a packed audience of eager dermatologists became prepared to deliver this year as well in the form of a digital series (Digital Conference [DIGICON]) for the benefit of all. The first DIGICON hosted on September 6, 2020, covered “The Mimickers in Pediatric Dermatology” and was followed successfully by the Second DIGICON based on “Primary Immunodeficiency Syndromes – What a Dermatologist Needs to Know” on September 20, 2020. All the speakers presented cases covering those from the obvious ones to those that one might see once in a while only and guided the audience with regard to the approach and workup required in these cases. The Third DIGICON hosted on October 4, 2020, was dedicated to “What's New in the Treatment of Atopic Dermatitis [Figure 1].” This was the Silver Jubilee commemorative session planned to compensate for the live spectacular conference that would have been otherwise hosted had times been rosy like the pre-COVID era. Nonetheless, the session began with greetings from Dr. Deepak Parikh, the moderator for the session, who took everyone through the journey of ISPD right from its inception. This was followed by the “e-naugural!” lamp lighting session, incorporated very beautifully keeping our culture and traditions intact. Dr. Parikh then introduced the key speaker of the evening Dr. Amy S. Paller, a Global Leader in Pediatric Dermatology and the President of the International Society of Pediatric Dermatology. Dr. Amy introduced the International Society and warmly welcomed the participation and involvement of anybody with a keen interest in pediatric dermatology. She then began her talk and enlightened all by her in-depth research and opinion on various new modalities available for the treatment of atopic dermatitis (AD). The key points highlighted were as follows:
- “Yardstick guidelines” recommendations for the management of AD
- “Proactive approach” (2)-short-term induction therapy with classical, intensive topical anti-inflammatory therapy until almost complete healing is achieved followed by a long-term, low-dose, usually twice weekly maintenance therapy of previously affected areas in combination with the usual emollient therapy of the entire skin surface
- Crisaborole 2% ointment shows an early and sustained improvement in disease severity and pruritus and other symptoms of AD. Burning and/or stinging upon application are the only related adverse events and hence should be applied with caution especially over the face
- Topical therapy is the cornerstone for management of AD and newer topicals are in the pipeline such as JAK inhibitors – topical ruxolitinib and delgocitinb. However, there is limited experience in the form of published reports
- Staphylococcus aureus drives inflammation and is associated with AD flares while the commensal bacteria play an important anti-inflammatory role. Coagulase-negative Staphylococcus (e.g., Staphylococcus hominis) produces antimicrobial factors that selectively kill S. aureus and may emerge as a potent topical therapy
- In a case of moderate–severe AD, even after adequate therapy, if an inadequate response is obtained, then consider nonadherence to therapy, misdiagnosis, or an infectious precipitate and re-evaluate
- Dupilumab has been studied well among the adult, adolescent, and child populations and has shown encouraging results. While initiating its use, always try to overlap it with ongoing medications for at least 1 month. If no response is seen even after 2 months of use, it shall probably not be effective at all
- There can be flares of AD even when on treatment with dupilumab, which can be managed by the use of potent topical anti-inflammatory agents
- Conjunctivitis associated with the use of dupilumab for AD could be a coincidental finding probably due to an altered mucosal barrier and deficiency of mucin-producing goblet cells due to the disease process per se. Prophylactic use of eye lubricants can be helpful.
After the wonderful and lucid talk by Dr. Amy S. Paller, a Q and A session followed which aptly summarized all that was discussed and its relevance in the Indian scenario. For example, topical tacrolimus still scores over topical crisaborole because of its similar efficacy, cost-effectiveness, and lesser side effect profile such as nontolerable burning sensation experienced with crisaborole. Further, that there is almost no role of omalizumab in the management of AD and that the dosing of dupilumab every 4 weeks has shown similar efficacy as compared to every 2 weeks dosing in practice.
As part of the silver jubilee celebrations, the ISPD had organized an essay writing competition on topics based on pediatric dermatology namely:
- Diet in Pediatric Dermatology
- Biologics in Pediatric Dermatology – Do We Need Them Yet?
- Pediatric Dermatology – Past, Present, and Future in India.
There were several participants throughout the country and all entries were anonymously judged by a panel of five experts who decided to award the best four essays. The winners of the ISPD essay competition 2020 were announced that evening as well and applauded for their skill and talent. The winners in the alphabetical order were Dr. Manjyot Gautam, Dr. Resham Vasani, Dr. Sahana Srinivas, and Dr. Sanober Daruwalla. The ISPD very graciously awarded a scholarship to each of the four awardees to attend the 14th Annual World Congress of Pediatric Dermatology 2021 at Edinburgh, UK. The 3rd ISPD DIGICON also showcased the journey and exponential growth achieved by the Indian Journal of Pediatric Dermatology (IJPD) under the erudite leadership of the Editor-in-Chief Dr. Sandipan Dhar. The evening was finally concluded by acknowledging and thanking the entire ISPD team that has worked effortlessly even beyond their call of duty with special acknowledgment to Dr. Arti Nanda, who true to her roots has supported and contributed to the society at large. The fourth and final session of the DIGICON series was conducted on November 1, 2020, and covered the topic “Diet and Atopic Dermatitis: What is New and What is News?” All speakers lucidly explained the relevance and importance of food allergy testing and the role of dietary restrictions in AD.
It is heartening to see that the ISPD led by the dynamic duo, Dr. Deepak Parikh and Dr. Sandipan Dhar with its core team as the backbone and pillar of strength, tirelessly working in creating awareness, spreading knowledge, and guiding all, including the young and old. The Society has created a profound impact for all interested and committed to the beautiful world of pediatric dermatology both nationally and internationally, and we hope that it continues its beautiful journey ahead and scales greater heights as many more years shall pass by.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.